MX2024013838A - Compuestos y usos de estos - Google Patents

Compuestos y usos de estos

Info

Publication number
MX2024013838A
MX2024013838A MX2024013838A MX2024013838A MX2024013838A MX 2024013838 A MX2024013838 A MX 2024013838A MX 2024013838 A MX2024013838 A MX 2024013838A MX 2024013838 A MX2024013838 A MX 2024013838A MX 2024013838 A MX2024013838 A MX 2024013838A
Authority
MX
Mexico
Prior art keywords
compounds
cancer
formula
present disclosure
pharmaceutically acceptable
Prior art date
Application number
MX2024013838A
Other languages
English (en)
Spanish (es)
Inventor
Shawn E R Schiller
Solymar Negretti
David S Huang
Kevin J Wilson
Melek Nihan Ucisik
Richard Caldwell
Original Assignee
Foghorn Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foghorn Therapeutics Inc filed Critical Foghorn Therapeutics Inc
Publication of MX2024013838A publication Critical patent/MX2024013838A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024013838A 2022-05-11 2024-11-08 Compuestos y usos de estos MX2024013838A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263340927P 2022-05-11 2022-05-11
PCT/US2023/021793 WO2023220219A1 (en) 2022-05-11 2023-05-11 Compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2024013838A true MX2024013838A (es) 2025-03-07

Family

ID=86732694

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013838A MX2024013838A (es) 2022-05-11 2024-11-08 Compuestos y usos de estos

Country Status (17)

Country Link
US (2) US12139487B2 (cg-RX-API-DMAC7.html)
EP (1) EP4522280A1 (cg-RX-API-DMAC7.html)
JP (2) JP7531656B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250024923A (cg-RX-API-DMAC7.html)
CN (1) CN119677738A (cg-RX-API-DMAC7.html)
AR (1) AR129299A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023270055A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252955A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003450A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024015229A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000231A (cg-RX-API-DMAC7.html)
IL (1) IL316531A (cg-RX-API-DMAC7.html)
JO (1) JOP20240250A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013838A (cg-RX-API-DMAC7.html)
PE (1) PE20250261A1 (cg-RX-API-DMAC7.html)
TW (2) TW202506693A (cg-RX-API-DMAC7.html)
WO (1) WO2023220219A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3198317A1 (en) * 2020-11-10 2022-05-19 Kevin J. Wilson Compounds and uses thereof
WO2025008060A1 (en) * 2023-07-05 2025-01-09 Janssen Pharmaceutica Nv 1,6-naphthridine compounds as smarca2 inhibitors useful for the treatment of smarca4 deficient cancers
WO2025099307A1 (en) * 2023-11-10 2025-05-15 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of diseases
US20250304542A1 (en) * 2024-03-11 2025-10-02 Enanta Pharmaceuticals, Inc. Fused Heterobicyclic Antiviral Agents
WO2025209520A1 (zh) * 2024-04-03 2025-10-09 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其用途
WO2025237242A1 (zh) * 2024-05-14 2025-11-20 上海和誉生物医药科技有限公司 一种smarca2抑制剂及其应用
CN118930537B (zh) * 2024-07-23 2025-05-13 上海信诺维生物医药有限公司 一种抑制brm的化合物
CN118930561B (zh) * 2024-07-23 2025-04-08 上海信诺维生物医药有限公司 一种稠环化合物
CN118908980B (zh) * 2024-07-23 2025-04-08 上海信诺维生物医药有限公司 一种多环化合物
WO2026046365A1 (zh) * 2024-08-30 2026-03-05 上海齐鲁制药研究中心有限公司 Smarca2抑制剂及其制备方法和用途
WO2026057002A1 (zh) * 2024-09-12 2026-03-19 江苏恒瑞医药股份有限公司 一种烯炔类化合物及其应用
WO2026061424A1 (zh) * 2024-09-18 2026-03-26 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其用途
WO2026131996A1 (en) * 2024-12-17 2026-06-25 Onco3R Therapeutics Bv Fused azines for the treatment of cancer
WO2026158636A1 (zh) * 2025-01-26 2026-07-30 江苏恒瑞医药股份有限公司 一种三环骨架芳酰胺类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007243466B2 (en) 2006-04-26 2012-01-19 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
SG10201900631TA (en) 2014-08-01 2019-02-27 Nuevolution As Compounds active towards bromodomains
BR112022015110A2 (pt) 2020-01-29 2022-11-08 Foghorn Therapeutics Inc Compostos e usos dos mesmos
BR112022015109A2 (pt) * 2020-01-29 2022-11-08 Foghorn Therapeutics Inc Compostos e usos dos mesmos
WO2021155264A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155262A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
CA3198317A1 (en) 2020-11-10 2022-05-19 Kevin J. Wilson Compounds and uses thereof

Also Published As

Publication number Publication date
TW202411228A (zh) 2024-03-16
AR129299A1 (es) 2024-08-07
JOP20240250A1 (ar) 2024-11-07
JP7531656B2 (ja) 2024-08-09
AU2023270055A1 (en) 2024-11-28
KR20250024923A (ko) 2025-02-20
CO2024015229A2 (es) 2025-03-06
TWI864749B (zh) 2024-12-01
CA3252955A1 (en) 2023-11-16
DOP2024000231A (es) 2024-12-15
PE20250261A1 (es) 2025-01-29
EP4522280A1 (en) 2025-03-19
JP2023168298A (ja) 2023-11-24
TW202506693A (zh) 2025-02-16
US20230365560A1 (en) 2023-11-16
IL316531A (en) 2024-12-01
CN119677738A (zh) 2025-03-21
US12139487B2 (en) 2024-11-12
WO2023220219A1 (en) 2023-11-16
US20250066354A1 (en) 2025-02-27
JP2024156779A (ja) 2024-11-06
CL2024003450A1 (es) 2025-03-14

Similar Documents

Publication Publication Date Title
JOP20240250A1 (ar) مركبات واستخداماتها
ZA202403923B (en) Heterocyclic compounds as immunomodulators
CR20230566A (es) Derivados de triazina y su uso en el tratamiento del cáncer
EP4520328A3 (en) Heterocyclic compounds as immunomodulators
PH12022552739A1 (en) Fused tricyclic kras inhibitors
MX2024001893A (es) Compuestos heterociclicos y metodos de uso.
MX2023012726A (es) Compuestos heterociclicos y metodos de uso.
MY209609A (en) Immunomodulators, compositions and methods thereof
MX2025000642A (es) Compuestos macrociclicos para el tratamiento de cancer
CR20230310A (es) Inhibidores de prmt5
WO2019173082A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
ZA202207667B (en) Sulfonimidamide compounds as nlrp3 modulators
MX2020013570A (es) Compuestos de purinona y su uso en el tratamiento del cancer.
MX2023005436A (es) Compuestos y usos de estos.
AU2020231934A8 (en) Compounds useful in HIV therapy
MX2024013842A (es) Benzoyparazina pirazinas y sus usos
WO2020210320A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
ZA202006071B (en) Antiproliferation compounds and uses thereof
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
MX2025001982A (es) Inhibidores de kif18a y usos de estos
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
WO2023102162A8 (en) Novel hdac inhibitors and therapeutic use thereof
MX2025001062A (es) Derivados de heteroaril sulfonamida biciclicos sustituidos para el tratamiento del cancer